A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Phase 1 : To evaluate MTD(Maximal tolerated dose)and DLT(Dose limiting Toxicity) of Belotecan and Ifosfamide.

Phase 2 : To analyse efficacy and toxicity of Belotecan and Ifosfamide.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gachon University Gil Medical Center
• Treatments: Belotecan; Camptothecin; Ifosfamide; Isophosphamide mustard

Criteria

Inclusion Criteria:

• histologically or cytologically confirmed extensive disease of Small cell lung cancer

• no prior chemotherapy or radiotherapy for lung

• measurable lesion for RECIST

• over 18 years

• ECOG 0~2

• expected life span more than 3 months

Exclusion Criteria:

• acute or active infection

• uncontrolled cerebral nerve symptoms or metastasis

• significant myocardial infarction or cardiac disease within 12 months